- The final surgeries in Presbia's (NASDAQ:LENS) pivotal Phase 3 clinical trial of its Flexivue Micolens are scheduled for next week, meeting the company's plan to complete the required enrollment in Q3. The product is designed to treat presbyopia or age-related loss of near vision.
- The estimated primary completion date (final data collection for the primary outcome measure) of the trial is December 2018. The estimated study completion date is February 2019. The primary endpoint is uncorrected near vision acuity of at least 20/40 at a distance of 40 cm.
- Flexivue is commercially available in the European Union and other countries around the world.